FDA Inspection
Wuhan Biocause Pharmaceutical Development Co., Ltd.Wuhan Biocause Pharmaceutical Development Co., Ltd. – FDA Inspection, Aug 24, 2018
Record Details
This FDA Inspection record concerns Wuhan Biocause Pharmaceutical Development Co., Ltd., with an inspection on August 24, 2018, issued by the Center for Drug Evaluation and Research, covering drugs.
- Inspection Date
- August 24, 2018
- Product Type
- Drugs
View Company Profile
ID · 58c8650e-e596-4fd1-a0ef-b54e39889c78
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1069379
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
Other FDA inspections of Wuhan Biocause Pharmaceutical Development Co., Ltd.
4| Date | Classification | Office | Project area |
|---|---|---|---|
| March 14, 2025 | Not classified | Office of Inspections and Investigations | |
| July 22, 2016 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| February 28, 2014 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| July 23, 2010 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Wuhan Biocause Pharmaceutical Development Co., Ltd.
- FDA Inspection 1267912 - 2025-03-14
- FDA Inspection 982641 - 2016-07-22
- FDA Inspection 873586 - 2014-02-28
- FDA Inspection 680329 - 2010-07-23
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.